Coronary/Structural Heart

HeartSciences to Present at the LD Micro Invitational XIV Conference

Coronary/Structural Heart by Comments are Disabled

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.

Continue Reading →

Innovating “Treadmill Exercise Test AI-Assisted Interpretation System,” CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Coronary/Structural Heart by Comments are Disabled

TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ — The treadmill exercise test (TET) is an important tool for diagnosing coronary artery disease (CAD), but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations. Traditionally,…

Continue Reading →

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Coronary/Structural Heart by Comments are Disabled

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Continue Reading →

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session & Expo

Coronary/Structural Heart by 0 comments

CAESAREA, Israel, March 28, 2024 /PRNewswire/ — V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind, placebo-procedure-controlled, multicenter, multinational, pivotal trial of the V-Wave® Ventura® Interatrial Shunt in symptomatic patients […]

Continue Reading →

Biome Analytics Introduces AI-Powered Documentation Audit Product to Enhance Cardiovascular Data Accuracy and Revenue Optimization

Coronary/Structural Heart by Comments are Disabled

SAN FRANCISCO–(BUSINESS WIRE)– #cardiology–Biome Analytics, the leader in cardiovascular performance improvement solutions, is pleased to announce the launch of its latest innovation, the Biome Risk Audit. Developed to address challenges in risk reporting and documentation accuracy in cardiovascular care, this artificial intelligence (AI) enabled tool integrates traditionally siloed quality data and billing information to improve publicly reported outcomes and maximize revenue opportunities. The Biome Ris

Continue Reading →

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Coronary/Structural Heart by Comments are Disabled

BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology’s Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunc

Continue Reading →

Polymedco announces US FDA clearance of the PATHFAST high-sensitivity cardiac troponin I (hs-cTnI-II) test as an aid in the diagnosis of myocardial infarction

Coronary/Structural Heart Regulatory by Comments are Disabled

PATHFAST hs-cTnI-II becomes first and only hs-cTn test cleared for point-of-care use in the United States, delivering results up to three times faster than core lab testing CORTLANDT MANOR, N.Y., March 27, 2024 /PRNewswire/ — The PATHFAST hs-cTnI-II, a breakthrough high-sensitivity…

Continue Reading →

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

Coronary/Structural Heart Regulatory by Comments are Disabled

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and…

Continue Reading →
1 … 89 90 91 92 93 … 430